The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
 
Derek B. Grose
Honoraria - BMSi; MSD Oncology
 
Nigel Balfour Jamieson
No Relationships to Disclose
 
Ganesh Radhakrishna
No Relationships to Disclose
 
Maria A. Hawkins
No Relationships to Disclose
 
David McIntosh
Honoraria - Ipsen; Novartis
Speakers' Bureau - Ipsen; Novartis
 
Aileen Duffton
No Relationships to Disclose
 
Janet Shirley Graham
Honoraria - Bayer; Bristol-Myers Squibb; Merck Serono; nucana
Consulting or Advisory Role - Merck KGaA
Travel, Accommodations, Expenses - nucana
 
Rebecca Goody
No Relationships to Disclose
 
Peter Houston
No Relationships to Disclose
 
Sarah Bradley
No Relationships to Disclose
 
Reena Ravikumar
No Relationships to Disclose
 
Alan Christie
No Relationships to Disclose
 
Judith Dixon-Hughes
No Relationships to Disclose
 
Caroline Kelly
No Relationships to Disclose
 
Lucy Paterson
No Relationships to Disclose
 
Andrew V. Biankin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology
 
Colin J. McKay
No Relationships to Disclose
 
David Kuang-Fu Chang
No Relationships to Disclose